Steve is a venture partner at Third Rock Ventures who brings more than 30 years of experience in medical oncology and the biotechnology industry. Prior to joining Third Rock Ventures, Steve was chairman and chief Executive Officer of Cell Genesys, a cancer immunotherapy company prior to its merger with BioSante Pharmaceuticals (now ANI Pharmaceuticals). He was also co-founder and chairman of Abgenix, an antibody company which was acquired by Amgen, and co-founder and chairman of Ceregene, a gene therapy company which was acquired by Sangamo Biosciences. Earlier in his career Steve served as vice president of clinical research at Genentech and was on the staff of the National Cancer Institute. In addition, Steve previously served as a director and chairman of the Biotechnology Innovation Organization and was a member of the President’s Council of Advisors in Science and Technology (PCAST) Working Group on Drug Development.
Steve is also Clinical Professor of Medicine at the University of California, San Francisco and a volunteer Attending Physician in Hematology-Oncology at the Zuckerberg San Francisco General Hospital where he is involved in patient care and teaching in his specialty of medical oncology. He is also a member of the scientific steering committee of the Parker Institute for Cancer Immunotherapy. Steve holds a B.A. in biology from Yale University, an M.D. from Harvard Medical School, and is board-certified in internal medicine and medical oncology and a fellow of the American College of Physicians.